Yair Lotan, MD, of UT Southwestern, discusses risk stratification in the STRATA trial and outlines the next steps for integrating Cxbladder triage into clinical workflows, including the potential for expanding its use beyond low-risk patients to include intermediate- and high-risk populations. He emphasizes that future guideline updates will likely depend on the performance of markers in ongoing and upcoming trials. ...
Urothelial Carcinoma Diagnostics
Advertisement
Dr. Lotan describes the design and key findings of the STRATA trial using Cxbladder Triage for patients with microhematuria.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
ctDNA testing may help identify patients with bladder cancer who would benefit from early post-cystectomy immunotherapy.
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
Dr. Sonpavde shares his thoughts on first-line therapy for aUC, including trials like CheckMate 274, AMBASSADOR, and NIAGRA.
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
WGS-based ctDNA detection offered a median lead time of 131 days over radiographic imaging.
Dr. Klümper highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to EV in mUC treatment.
How can clinical tools like circulating tumor DNA inform bladder cancer treatment adjustments and transitions?
Advertisement
Video Insights
Conference Coverage
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Sanchez-Salas comments on whether PSMA PET is useful for determining optimal candidates for focal therapy.
Dr. Sanchez-Salas details strategies for selecting between focal therapy versus active surveillance or definitive treatments.
Dr. Kaouk presented on the benefits of surgery for managing biochemically recurrent prostate cancer post-radiation.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.